Top Management Presentation
Financial Results of FY2017 Q1

from the beginning

Top Management Presentation Financial Results of FY2017 Q1

Forward-Looking Statements

Agenda

FY2017 Q1 Financial Results

Overview of FY2017 Q1 Results

Revenue

Operating Profit

Profit Attributable to Owners of the Company

Revenue: Major Business Units (Incl. Forex impact)

Revenue: Major Products in Japan

Major Management Topics

Edoxaban Update

Growth in Japan

Growth in Japan

Growth in Germany and South Korea

LCM update

Japan Business Update

Expansion of Product Portfolio in Japan

Expansion of Product Portfolio in Japan

Injectafer Update

Growth of Injectafer

Injectafer Life-Cycle Management

Business Growth in China

Establish Efficient Structures and Expand Revenue

Enhance Production Capacity for Business Expansion

R&D Update

Mirogablin: Phase 3 Result and Future Schedule

Presentation at ASCO 2017

DS-8201: ASCO 2017 (Oral)

DS-8201: ASCO 2017 (Oral)

DS-8201: ASCO 2017 (Oral)

DS-8201: ASCO 2017 (Oral)

DS-8201: ASCO 2017 (Oral)

DS-8201: ASCO 2017 (Oral)

DS-8201: ASCO 2017(Poster)

U3-1402: ASCO 2017 (Poster)

DS-8201: Future Schedule

U3-1402: Future Schedule

DS R&D Day 2017

FY2017 Major R&D Milestone Events

Major R&D Pipeline

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5